CLOSED

GET A PIECE OF ONEFUL HEALTH, INC.

Making Medicines Work Better For You

OneFul is a pharmacy tech enterprise that has developed novel drug delivery products using patented automation and personalized medicine formulation software. In 2021, the company’s accredited pharma facility generated $5.8M in consolidated annual revenue, over $3M thru Q3 2022.

Show more

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Company Image

REASONS TO INVEST

Reasons Icon

Our innovative cardiovascular "polypill" combines 3-7 FDA-approved pharmaceuticals into a single capsule or gel packet tailored to your medical needs. In studies, our formulations have been shown to reduce the risk of heart attacks and strokes by 50% per year

Reasons Icon

Our robotic automation and online tools enable us to produce personalized treatments in partnership with telemedicine physicians at a price point as low as $1 per day, making personalized medications affordable and accessible to almost everyone.

Reasons Icon

Invest in OneFul to tap into the personalized medicine industry, which experts indicate that the industry will soon be a trillion-dollar sector. Unlike traditional “One-size-for-all” medicine, our precision technology combined with the latest pharmacogenomics science has the potential to transform healthcare by providing individualized therapies on a mass scale. Our team is equipped with patented robotics, multi-state accredited pharmacy licenses, and an entire operational pharmacy staff. The OneFul pipeline includes customized treatments for major chronic diseases such as diabetes, mental health, and Alzheimer's in the future. Don't miss out on the opportunity to revolutionize healthcare.

TEAM

Edison T Hudson

Edison T Hudson • CEO/CTO/Board Member/Founder

Edison is a serial entrepreneur with multiple exits and IPO experience. He is also recognized as a prolific inventor with over 30 patents, spending over 15 years in semiconductor automation in Silicon Valley and the EU. At iRobot Corporation, as Director of Research, he participated on the IPO team and led new business acquisitions and strategic technology roadmap analysis. His engineering and computer science expertise is combined with street-savvy business acumen, having concluded dozens of technology licenses and partnership agreements. He is a lifelong learner and researcher, a Morehead Scholar at the University of North Carolina, an MBA from Duke University, and studied machine learning and robotics at Oxford University U.K., where he spun out his first company. An excellent communicator, he was a speaker at the 2022 Precision Medicine World Conference in Silicon Valley. His passion and vision are that robotics and machine learning can democratize health using low-cost, safe, and more effective personalized treatments. He has assembled a team of experts and operational management that can leverage post-pandemic regulatory change. This team and his inventions are the foundation for a scalable digital health paradigm, economically delivering the benefits of personalized medicine to millions.

(Fulltime Employee)

Read More

Danny M Barnes

Danny M Barnes • Chief Pharmacy Officer, Board Member, President Triangle Compounding Pharmacy

Danny has spent the last 20 + years focused on serving patients and physicians with personalized sterile and non-sterile medications for complex needs. As president and operational executive of Triangle Compounding Pharmacy (TCP), the wholly owned compounding pharmacy operation of Oneful, he drove TCP to be the first compounding pharmacy in NC to meet national standards and be accredited by the Pharmacy Compounding Accreditation Board (PCAB). TCP was the first compounding pharmacy in NC to be registered as a Human Drug Outsourcing Facility (503B) to help physicians and hospitals meet critical patient needs by compounding crucial medications during drug shortages. Danny received his Pharm.D. from Campbell University and his Zoology degree at NC State University. As Chief Pharmacy Officer of Oneful Health, he is passionate about implementing cGMP quality robotic automation to modernize compounding pharmacy. His devotion to the highest quality products and services has generated a large, loyal community of patients and healthcare systems. He shares his regulatory and operational expertise through activities with state and national pharmacy organizations.

(Fulltime Employee)

Read More

Deon Joubert

Deon Joubert • Chairman of Board

Deon represents the Sanitarium Health & Wellbeing Group (AUS), a significant investor in Oneful Health Inc, where he has the role of Executive General Manager - Treasury & Advisory. Sanitarium is one of Australia/New Zealand's largest health food companies, which also operates major hospital facilities there. Deon has responsibility for a range of treasury and finance functions, banking, insurance, legal and M&A. Deon serves as director and/or secretary for most of the Sanitarium Health & Wellbeing Group entities and, as part of the Group’s executive, reports to the Chief Executive Officer. 

(Outside Board Member)

Read More


the pitch

OneFul Health's mission is to improve the quality of life for millions of patients, through personalized medicine produced with patented pharmacy technology. Our e-pharmacy platform combines precision medicine science and robotic automation to create multi-drug prescriptions as a capsule or easy-to-swallow gel packet. The company is currently focused on launching its personalized “polypill” product for cardiovascular patients and plans to scale to additional markets and health conditions, including mental health and diseases of aging,  in the next few years.




A Prescription for Efficient, Individualized Pharmaceutical Therapy

OneFul’s pharmaceutical technology platform is being designed to offer affordable and accessible prescription combination medications, customizable to a variety of health conditions and chronic diseases at the individual level.


*A patented gel packet system has been used in high volume production of personalized nutraceuticals and is planned to be qualified for pharmaceuticals pending bioequivalence testing.


Utilizing patented processes and innovative drug delivery technology, our digital platform is designed to consolidate many approved medications into a single capsule format, with a goal of improving patient adherence, and reducing any adverse effects from treatment. Our regulatory licenses allow us to go to market now without the uncertainty of government approvals using approved pharmaceuticals in high-purity forms. We work with partners who supply genomic analysis and digital health data, and algorithms to formulate each prescription to be the most effective combination of treatments possible for each person. 

The Problem & Our Solution


A Scalable Platform Built To Support Tens of Millions with Effective Chronic Disease Treatments 

For consumers managing chronic diseases and conditions, current drug therapies typically consist of multiple medications, requiring patients to take as many as 3-7 pills per day. According to recent data, 24% of adults in the U.S. take more than 3 pills per day and the rate of adherence to prescribed treatments is less than 50% (source, source), resulting in at least 100,000 preventable deaths, and $100B in preventable medical costs per year. (source)


In order to consolidate existing prescriptions as well as improve treatment outcomes, OneFul has developed the technology to combine multiple approved drugs and produce a single small capsule or flavored gel packets, containing high-purity doses of the same active drug ingredients. 


*A patented gel packet system has been used in high volume production of personalized nutraceuticals and is planned to be qualified for pharmaceuticals pending bioequivalence testing.


Our patented automation platform is capable of producing formulas on-demand, more accurately, and up to 100 times faster than traditional manual compounding, resulting in low-cost, highly-customized, multi-drug treatments. Many of our products cost as little as $1 per day and can be additionally personalized with microdosing to best suit the drug metabolism of each individual patient.

The Market & Our Traction


The Demand and Capacity to Change Personalized Medicine 

OneFul’s e-pharmacy has built a customer base of over loyal 3,500 patients, generating annual revenues of over $5M. 15-20% of existing customers surveyed indicate an interest in the cardiovascular polypill concept, translating to a potential waitlist of hundreds. We are in the process of negotiating contractual relationships with partners that include physician telemedicine networks, cardiology specialists, concierge clinics, and has had development contracts with major hospital systems. 



In order to meet growing demand, OneFul is building a direct-to-patient ecommerce platform, and, at present, the company has secured more than 13 patents for its robotic automation, personalized medicine process methods, and pharma-tech. Our strategic roadmap entails automation of 500 unique scripts per month by Q3 of 2023, and we believe we may incrementally increase monthly capacity to 5K by Q4 and 10K by mid-2024.


*A patented gel packet system has been used in high volume production of personalized nutraceuticals and is planned to be qualified for pharmaceuticals pending bioequivalence testing.

Why Invest


Help Simplify Medications and Grow a New Kind of Pharmaceutical Solution 

In OneFul’s opinion, we possess a unique opportunity built on an accredited established business combined with unmatched IP and innovation. We are on track to serve thousands of existing customers, and to reach millions of chronic disease sufferers, improving their health and daily quality of life. 


As of 2021, the company had successfully raised over $7M in funding which has been instrumental in developing our IP and building a commercial operation. 


Our future plans include market promotion, new partnerships, and scaling existing production operations to accommodate the growing demand for personalized therapies. Thank you for your investment in OneFul Health!



Click here to see if you qualify for our polypill!

ABOUT

HEADQUARTERS
6 Davis Drive
Durham, NC 27709
WEBSITE
View Site
OneFul is a pharmacy tech enterprise that has developed novel drug delivery products using patented automation and personalized medicine formulation software. In 2021, the company’s accredited pharma facility generated $5.8M in consolidated annual revenue, over $3M thru Q3 2022.

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.

www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.

Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary LLC (“SE Primary”), a broker-dealer registered with the SEC and FINRA / SIPC. You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system (ATS) regulated by the SEC and operated by SE Primary. SE Primary is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

StartEngine facilitates three types of primary offerings:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice concerning any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy, or completeness of any information. Neither StartEngine nor any of its officers, directors, agents, and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks, and you should complete your own independent due diligence regarding the investment. This includes obtaining additional information about the company, opinions, financial projections, and legal or other investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment. See additional general disclosures here.

By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors

Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.

StartEngine Marketplace (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC.

StartEngine Secondary (“SE Secondary”) is our investor trading platform. SE Secondary is an SEC-registered Alternative Trading System (“ATS”) operated by SE Primary that matches orders for buyers and sellers of securities. It allows investors to trade shares purchased through Regulation A+, Regulation Crowdfunding, or Regulation D for companies who have engaged StartEngine Secure LLC as their transfer agent. The term “Rapid,” when used in relation to transactions on SE Marketplace, specifically refers to transactions that are facilitated on SE Secondary, This is because, unlike with trades on the StartEngine Bulletin Board (“SE BB”), trades on SE Secondary are executed the moment that they are matched.

StartEngine Bulletin Board (“SE BB”) is a bulletin board platform on which users can indicate to each other their interest to buy or sell shares of private companies that previously executed Reg CF or Reg A offerings not necessarily through SE Primary. As a bulletin board platform, SE BB provides a venue for investors to access information about such private company offerings and connect with potential sellers. All investment opportunities on SE BB are based on indicated interest from sellers and will need to be confirmed. Even if parties express mutual interest to enter into a trade on SE BB, a trade will not immediately result because execution is subject to additional contingencies, including among others, effecting of the transfer of the shares from the potential seller to the potential buyer by the issuer and/or transfer agent. SE BB is distinct and separate from SE Secondary. SE Secondary facilitates the trading of securities by matching orders between buyers and sellers and facilitating executions of trades on the platform. By contrast, under SE BB, SE Primary assists with the facilitation of a potential resulting trade off platform including, by among other things, approaching the issuer and other necessary parties in relation to the potential transaction. The term “Extended”, when used in relation to transactions on SE Marketplace denotes that these transactions are conducted via SE BB, and that these transactions may involve longer processing times compared to SE Secondary for the above-stated reasons.

Even if a security is qualified to be displayed on SE Marketplace, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.

The availability of company information does not indicate that the company has endorsed, supports, or otherwise participates with StartEngine. It also does not constitute an endorsement, solicitation or recommendation by StartEngine. StartEngine does not (1) make any recommendations or otherwise advise on the merits or advisability of a particular investment or transaction, (2) assist in the determination of the fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.